Metformin + Vildagliptin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Type 2 diabetes mellitus
Adult: Each tab contains vildagliptin (mg)/metformin (mg): 50/500, 50/850, or 50/1,000: 1 tab bid based on patient’s current regimen, effectiveness, and tolerability. Max: Vildagliptin: 100 mg daily.
Suy thận
Severe (GFR <30 mL/min): Contraindicated.
Suy gan
Contraindicated.
Cách dùng
Should be taken with food. Take w/ or immediately after meals to reduce GI discomfort.
Chống chỉ định
Acute metabolic acidosis (e.g. lactic acidosis, diabetic ketoacidosis); conditions which may alter renal function (dehydration, severe infection, shock); acute or chronic disease which may cause tissue hypoxia (e.g. cardiac or resp failure, recent MI, shock); undergoing surgery. Acute alcohol intoxication. Lactation. Severe hepatic and renal (GFR <30 mL/min) impairment. Intravascular admin of iodinated contrast agents.
Thận trọng
Patient w/ history of acute pancreatitis. Mild to moderate renal impairment. Pregnancy. Not intended for the treatment of type 1 DM and diabetic ketoacidosis.
Tác dụng không mong muốn
Significant: Dehydration, acute pancreatitis, bullous and exfoliative skin lesions, decreased vit B12 levels, hypoglycaemia. Rarely, hepatic dysfunction (i.e. hepatitis).
Nervous: Dizziness, tremor, headache, fatigue.
GI: Nausea, diarrhoea.
Dermatologic: Hyperhidrosis.
Potentially Fatal: Rarely, lactic acidosis.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor LFTs prior to initiation, during treatment at 3-mth intervals during the 1st yr, and periodically thereafter; and renal function regularly.
Tương tác
Delayed elimination of metformin w/ cationic active substances eliminated by renal tubular secretion (e.g. cimetidine). Increased risk of lactic acidosis w/ ACE inhibitors, angiotension receptor antagonists, diuretics, NSAIDs. Increased risk of angioedema w/ ACE inhibitors. Thiazide diuretics, corticosteroids, phenothiazines, thyroid products, OC, sympathomimetics, phenytoin, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control.
Potentially Fatal: Intravascular admin of iodinated contrast agents may cause contrast-induced nephropathy, leading to increased risk of lactic acidosis.
Tương tác với thức ăn
Food decreases the extent and slightly delays absorption. Increased risk of lactic acidosis w/ alcohol.
Tác dụng
Description: Metformin is a biguanide antidiabetic agent that decreases hepatic glucose production via inhibition of gluconeogenesis and glycogenolysis, improves peripheral utilisation and uptake of glucose by increasing insulin sensitivity, and delays intestinal glucose absorption. Vildagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), thereby increasing the concentration of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This enhances glucose-dependent insulin secretion and reduces glucagon production.
Pharmacokinetics:
Absorption: Metformin: Slowly and incompletely absorbed from the GI tract. Absolute bioavailability: Approx 50-60%. Time to peak plasma concentration: Approx 2.5 hr. Vildagliptin: Rapidly absorbed from the GI tract. Bioavailability: 85%. Time to peak plasma concentration: Approx 1.7 hr.
Distribution: Metformin: Partitions into erythrocytes; crosses the placenta and enters breast milk in small amounts. Volume of distribution: 63-276 L. Vildagliptin: Distributed equally between plasma and RBCs. Plasma protein binding: 9.3%.
Metabolism: Vildagliptin: Metabolised (69%) in the kidney via hydrolysis into the major inactive metabolite, LAY-151.
Excretion: Metformin: Via urine (90% as unchanged drug). Terminal elimination half-life: Approx 6.5 hr. Vildagliptin: Via urine (85%, 23% as unchanged drug) and faeces (15%). Elimination half-life: Approx 3 hr.
Đặc tính

Chemical Structure Image
Metformin

Source: National Center for Biotechnology Information. PubChem Database. Metformin, CID=4091, https://pubchem.ncbi.nlm.nih.gov/compound/Metformin (accessed on Jan. 20, 2020)


Chemical Structure Image
Vildagliptin

Source: National Center for Biotechnology Information. PubChem Database. Vildagliptin, CID=6918537, https://pubchem.ncbi.nlm.nih.gov/compound/Vildagliptin (accessed on Jan. 22, 2020)

Bảo quản
Store below 30°C. Protect from moisture.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BD08 - metformin and vildagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Metformin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/06/2017.

Buckingham R (ed). Metformin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/06/2017.

Buckingham R (ed). Vildagliptin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/06/2017.

Joint Formulary Committee. Vildagliptin with Metformin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/06/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Metformin Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 15/06/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Metformin + Vildagliptin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in